Ophthalmological Therapeutics: Pipelines, Delivery Technologies, and Markets

Table of Contents

• A BRIEF INTRODUCTION TO OPHTHALMOLOGY AND ITS MARKETS
• 1.1. The Eye and Its Disorders
• 1.2. The Ophthalmology Market
• 1.3. High Unmet Medical Need and Scientific Challenges

• THE HUMAN EYE: A UNIQUE THERAPEUTIC TARGET
• 2.1. Anatomy of the Visual Apparatus
• 2.2. Characterizing and Quantifying Vision
• 2.3. Eye Surgery
  • Surgery for the Inner Eye
  • Surgical Correction of Opacification or Refractive Deviations
• 2.4. Ophthalmological Drug Delivery: Barriers and Strategies

• DISORDERS OF THE ANTERIOR EYE: WHAT YOU CAN SEE IS NOT ALWAYS EASY TO TREAT
• 3.1. Dry Eye Syndrome
  • Existing Products for Dry Eye
  • Restasis
  • Advanced-Stage Investigational Drugs for Dry Eye
  • Early Experimental Therapeutic and Diagnostic Approaches to Dry Eye
• 3.2. Allergic Conjunctivitis
  • New Developments
• 3.3. Corneal Lesions and Dystrophy
• 3.4. Superficial Eye Infections
  • Infectious Conjunctivitis and Other "Simple" Anterior Eye Infections
  • AzaSite: The First Ophthalmic Azithromycin
  • Antibiotic and Combination Products in Development
• 3.5. Tropical Eye Infections Make Inroads
  • Atypical Keratitis: A Growing Problem in Temperate Climate Zones
  • Trachoma: The World' s Leading Cause of Preventable Blindness
  • River Blindness
• 3.6. Cataracts: Aging and Denaturation of the Lens
  • A Sector Dominated by Surgery
  • An Uphill Struggle for Drug Development
  • Pharmacoprevention for Posterior Capsule Opacification
  • Lens Regeneration and Tissue Biotechnology
• 3.7. Glaucoma: Pressure in the Front, Neurodegeneration in the Back of the Eye
  • Drugs for Intraocular Pressure Reduction
  • The Current Drug Landscape for Glaucoma
  • New Developments in the Glaucoma Drug Field

• DISORDERS OF THE POSTERIOR EYE: AT THE SITE OF VISION
• 4.1. Vitrectomy: Radical Back-Eye Surgery for Multiple Causes
  • Vitreous Replacements
  • Preventing Formation of Cataracts as a Complication of Vitrectomy
  • Vitrase/Vitragan: A Potential Alternative to Vitrectomy for Hemorrhages
• 4.2. Diabetic Retinopathy and Retinal Vein Occlusion: A Lifestyle Disorder That Blinds
  • Laser Photocoagulation
  • Triamcinolone: Not Approved, but Widely Used, for DME
  • Ruboxistaurin: A Troubled Oral Drug Candidate for DME
  • More Experimental Drug Candidates for Retinopathy: The New and the Old
• 4.3. Age-Related Macular Degeneration: The Leading Cause of Blindness in the Industrialized World
  • Blood Vessel Sensitization to Phototherapy in Wet AMD
  • Visudyne: The Pioneer
  • Photrex and Optrin: 2 Follow-Up Photosensitizers
  • Biotechnology Anti-VEGF Products: Rise of a Class
  • Macugen
  • Lucentis
  • Avastin: Off-Label Use in AMD and the Supply Restrictions Controversy
  • Follow-Up Developments in Ocular VEGF Control
  • Beyond VEGF: A Failure, and Many Hopes
  • Noninvasive Clinical Product Developments for AMD
  • Vigorous Preclinical and Patenting Activity Indicates More Approaches Under Way
• 4.4. Retinitis Pigmentosa: The Most Frequent Inherited Eye Disease
• 4.5. Intraocular Melanoma and Retinoblastoma: Posterior Eye Oncology
  • Choroidal Melanoma
  • Retinoblastoma

• SIZE, STRUCTURE, AND DYNAMICS OF THE OPHTHALMOLOGICAL PHARMACEUTICAL MARKET
• 5.1. Small Innovators, Large Marketers
  • Alcon Laboratories
  • Allergan
  • Bausch & Lomb
  • Senju Pharmaceutical
  • Fovea Pharmaceuticals
  • ISTA Pharmaceuticals
  • MacuSight
  • Novagali Pharma
  • Ocularis Pharma
  • OSI Eyetech
  • OPKO Health
  • Othera Pharmaceuticals
  • Sirion Therapeutics
• 5.2. A Habitat for Specialized CROs
  • Iris Pharma and Clirophtha
  • PharmaNet Ophthalmology Group
  • Rx Development Resources
  • Global Clinical Trials Ophthalmology Research Services
• 5.3. Ophthalmological Market Dynamics and its Drivers
  • Demographics
  • Lifestyle
  • Capital Flows into the Ophthalmological Drug Development Market
• 5.4. Modeling the Ophthalmological Drug Market: Perspectives for 2015-2020

• EXPERT INTERVIEWS: A VIRTUAL ROUNDTABLE
• Cedric Francois, MD, PhD
  • President and CEO
  • Potentia Pharmaceuticals, Louisville, KY
• Avner Ingerman, MD
  • Vice President and Ophthalmology Team Leader
  • Regeneron Pharmaceuticals, Tarrytown, NY
• Samuel Reich
  • Executive Vice President of Ophthalmologics
  • OPKO Health
  • Miami, FL
• Roger Vogel, MD
  • Cofounder and Chief Medical Officer
  • Sirion Therapeutics, Tampa, FL
• REFERENCES
• COMPANY INDEX WITH WEB ADDRESSES